Evidence map›Paper›PMID 41532325›Full record

Observational studyDiabetes, obesity & metabolism2026

Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.

Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Louis TalayFaculty of Arts and Social Sciences, University of Sydney SDN, Camperdown, Sydney, New South Wales, Australia.ORCID 0000-0002-5390-8392
Jason HomDepartment of Medicine, Stanford University Medical Centre, Stanford, California, USA.
Tamara ScottDepartment of Medicine, Stanford University Medical Centre, Stanford, California, USA.
Neera AhujaDepartment of Medicine, Stanford University Medical Centre, Stanford, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsObesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real-world evidence in digital weight-loss services (DWLSs) is limited. This retrospective study evaluated 6- and 12-month weight loss, adherence and predictors of outcomes in an Australian cohort using a tirzepatide-supported medicated DWLS. MATERIALS AND

methodsAll patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed. The study population was predominantly female (92.9%) and Caucasian (81.9%), with a mean age of 41.46 years and a mean baseline body mass index of 32.9 kg/m

resultsAt 6 months, 31.7% met adherence criteria; mean weight loss among adherent patients was 16.9% (±8.6; 95% CI 16.6-17.2), with 98.0% achieving ≥5% weight reductions. At 12 months, 16.1% were adherent; mean weight loss was 22.7% (±7.2; 95% CI: 19.8-22.6) and 100% of patients reached the ≥5% milestone. Multivariable models identified 1-month weight loss as the strongest predictor of 6- and 12-month outcomes; sustained weekly weight tracking and health coach messaging were strongly associated with both retention and greater weight loss. Paradoxically, very frequent weight tracking in month one correlated with poorer outcomes and reduced retention. Side effects were common but mostly mild/moderate and did not correlate with weight loss or programme retention.

conclusionsTirzepatide plus multidisciplinary digital care yields large clinically meaningful weight loss among engaged users, but low adherence limits population-level effectiveness. Early clinical response and sustained engagement are key drivers of adherence; however, interventions are needed to manage early weight-loss expectations.

Indexed as

Anti-Obesity AgentsObesityPatient ComplianceTirzepatideWeight Reduction ProgramsAdultAustraliaDigital HealthFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeWeight LossAnti-Obesity AgentsTirzepatideantiobesity drugobesity careobservational studypatient reported outcomesreal‐world evidenceweight management

Identifiers

PMID41532325
PMCPMC12992185

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.